In a phase 3 trial by the Italian FIL group, lenalidomide post ASCT was shown to improve PFS,60 and in the 2nd European MCL Network Elderly trial, the addition of lenalidomide to rituximab maintenance (R2) prolonged PFS compared with rituximab alone.61 European groups have also explored the use of BTK and BCL2 inhibitors in untreated patients with MCL, such as the combination of rituximab and ibrutinib (IR) in low-risk MCL by the Spanish group,62 and the addition of venetoclax consolidation after R-BAC63 in elderly high-risk MCL. The gene discussed is BCL2; the disease is mantle cell lymphoma.